Nevertheless, although there are currently no approved myostatin inhibitors for the treatment of sarcopenia due to still limited efficacy, especially in terms of increasing physical performance, several studies and clinical trials have demonstrated that the inhibition of the myostatin and activin signaling pathways is still a promising area for further research into novel drug formulations for sarcopenia and possibly also osteosarcopenia. This evidence concerns the gene MSTN and sarcopenia.